<DOC>
	<DOCNO>NCT00195871</DOCNO>
	<brief_summary>The primary objective study evaluate safety efficacy adult `` acute lymphoblastic leukaemia '' type chemotherapy patient less 60 year lymphoblastic lymphoma . Treatment principle base intensive induction delay intensification .</brief_summary>
	<brief_title>Safety Efficacy Adult Acute Lymphoblastic Leukemia Chemotherapy Adult Lymphoblastic Lymphoma</brief_title>
	<detailed_description>Lymphoblastic lymphoma ( LL ) rare represent le 2 % malignant non-Hodgkin lymphoma ( NHL ) . The distinction LL acute lymphoblastic leukaemia ( ALL ) difficult ; arbitrarily base percentage medullary blast . Above 20 % blast , ALL . In case , type cell affect : lymphoblast . Thus LL treat either aggressive NHL ALL . The result various clinical study , show best efficacy ALL type treatment ( term overall survival disease free survival ) . These treatment base induction phase reinforce cyclophosphamide L-asparaginase , re-use first drug consolidation ( delay intensification ) . The prognostic factor ALL good define , determine risk group . According prognostic indicator , allograft could propose first complete remission . Indicators biological ( hyperleukocytosis , chromosomal abnormality ( 4 ; 11 ) , ( 9 ; 22 ) , ( 1 ; 19 ) translocation ) , clinical ( central nervous system involvement ) , evolutive ( salvage therapy need obtain complete remission ) , consideration early response ( cortico-sensibility chemo-sensibility ) molecular response ( residual disease ) . On hand , prognostic factor LL well known . This study permit good define . So prognostic indicator ALL , study , decisional indication allograft . This treatment base parallel currently recruit adult patient ALL ( protocol GRAALL 2003 ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Patient lymphoblastic lymphoma . Aged 18 59 year . Medullary blast rate le 20 % Non previously treat With without central nervous system meningeal involvement . No contraindication anthracyclines . No contraindication intensive treatment Negative HIV serology test Negative pregnancy test female patient childbearing potential . Able regularly follow . Evolutive cancer exception non melanoma skin tumour stage 0 ( situ ) cervical carcinoma . Prior treatment chemotherapy . Lymphoblastic Transformation chronic myeloid leukaemia Patient unable regularly followedup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Non-Hodgkin</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphoblastic</keyword>
</DOC>